We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Synairgen Plc | LSE:SNG | London | Ordinary Share | GB00B0381Z20 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 4.65 | 4.52 | 4.99 | - | 172,565 | 10:52:51 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 0 | -17.65M | -0.0876 | -0.53 | 9.36M |
| Date | Subject | Author | Discuss |
|---|---|---|---|
| 18/6/2020 17:47 | Given no one knows the results yet, it can't be based on efficiency. What they do know is that it's safe and that Interfrons are known substances (including being used in a 3 drug trial), repurposed here. Given the number of background papers around Infa working, it's most likely the 2nd of your suggestions It's also worth saying that currently, there are no home based therapies, as far as I know, so it's a 1st in a number of ways. | waterloo01 | |
| 18/6/2020 17:40 | Surely someone on here must know whether the NHS would be agreed to widen the trial parameters for SNG if it didnt have good reason to do so (ie SNG's treatment was showing statistically significant improvements in the underlying patients?) or is the NHS just making sure the trial significantly large enough to either validate or disprove SNG? Wish I knew....... | mdchand | |
| 18/6/2020 17:28 | Hi Nobby, can you allow me access into the guild? Have been using the filter a lot lately, but now missing out on the decent posters and want to stay up to date with SNG,Thanks in advance, Mark | sipster |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
